TGFB1 and systemic lupus erythematosus: In SLE patients treated with Edratide subcutaneously, the expression of pathogenic cytokines, such as IL-1β, TNF-α, IFN-γ, and BLyS, were significantly downregulated, but the expression of anti-inflammatory cytokine TGF-β was increased (13).